Veracyte (VCYT) Research & Development (2012 - 2026)

Veracyte has reported Research & Development for 15 years, with the latest figure at $29.4 million in Q2 2026.

• Research & Development for Q2 2026 came in at $29.4 million, up 16.3% year-over-year; the trailing twelve-month figure through Jun 2026 was $107.0 million (up 10.07% YoY), and the FY2025 annual result was $100.2 million, up 4.96% from the prior year.
• Research & Development climbed to $29.4 million in Q2 2026, from $27.2 million in the prior quarter.
• Over five years, Research & Development peaked at $29.4 million in Q2 2026 and troughed at $22.6 million in Q3 2024.
• A 5-year average of $25.1 million and a median of $24.6 million in 2024 frame the typical range for Research & Development.
• The widest annual swing landed in 2022, when Research & Development soared 45.77%; it then slipped 8.99% in 2024.
• A 5-year view of Research & Development shows it stood at $24.1 million in 2022, then gained by 4.7% to $25.3 million in 2023, then decreased by 1.73% to $24.8 million in 2024, then increased by 4.5% to $25.9 million in 2025, then advanced by 13.5% to $29.4 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $29.4 million in Q2 2026, $27.2 million in Q1 2026, and $25.9 million in Q4 2025.